Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

Autor: Marc-Andrea Baertsch, Elias K. Mai, Thomas Hielscher, Uta Bertsch, Hans J. Salwender, Markus Munder, Stephan Fuhrmann, Ulrich Dührsen, Peter Brossart, Kai Neben, Jana Schlenzka, Christina Kunz, Marc S. Raab, Jens Hillengaß, Anna Jauch, Anja Seckinger, Dirk Hose, Steffen Luntz, Pieter Sonneveld, Henk Lokhorst, Hans Martin, Martin Goerner, Martin Hoffmann, Hans-Walter Lindemann, Helga Bernhard, Igor W. Blau, Christof Scheid, Britta Besemer, Katja C. Weisel, Mathias Hänel, Jan Dürig, Hartmut Goldschmidt, German-Speaking Myeloma Multicenter Group (GMMG)

Publikováno v: Blood Cancer Journal, Vol 11, Iss 1, Pp 1-10 (2021)

Abstract Lenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma (MM) but has not been compared to other agents in clinical trials. We retrospectively compared borte

Externí odkaz: https://doaj.org/article/c1262202ec704fb3bc2b8009125681e4

Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment

Autor: Katharina Kriegsmann, Michael Hundemer, Nicole Hofmeister-Mielke, Philipp Reichert, Calin-Petru Manta, Mohamed H.S. Awwad, Sandra Sauer, Uta Bertsch, Britta Besemer, Roland Fenk, Mathias Hänel, Markus Munder, Katja C. Weisel, Igor W. Blau, Andreas Neubauer, Carsten Müller-Tidow, Marc S. Raab, Hartmut Goldschmidt, Stefanie Huhn, for the German-speaking Myeloma Multicenter Group (GMMG)

Publikováno v: Cancers, Vol 12, Iss 2322, p 2322 (2020)
Cancers
Volume 12
Issue 8

In order to meet the challenges in data evaluation and comparability between studies in multiple myeloma (MM) minimal residual disease (MRD) assessment, the goal of the current study was to provide a step-by-step evaluation of next-generation sequenc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3069fbc3c5a12f6bb9530d5e1aaaf56f
https://www.mdpi.com/2072-6694/12/8/2322

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

Autor: Markus Munder, Hartmut Goldschmidt, Hans Salwender, Marc S. Raab, Jana Schlenzka, Martin Goerner, Marc-Andrea Baertsch, Martin Hoffmann, Peter Brossart, Dirk Hose, Anna Jauch, Jan Dürig, Stephan Fuhrmann, Steffen Luntz, Christina Kunz, Jens Hillengaß, Hans-Walter Lindemann, Kai Neben, Elias K. Mai, Henk M. Lokhorst, Thomas Hielscher, Ulrich Dührsen, Igor Wolfgang Blau, Hans Martin, Mathias Hänel, Pieter Sonneveld, Christof Scheid, Katja Weisel, Uta Bertsch, Helga Bernhard, Anja Seckinger, Britta Besemer

Publikováno v: Blood Cancer Journal
German-Speaking Myeloma Multicenter Group (GMMG) 2021, ' Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma ', Blood cancer journal, vol. 11, no. 1, 1 . https://doi.org/10.1038/s41408-020-00390-3
Blood Cancer Journal, 11(1):1. Nature Publishing Group
Blood cancer journal, 11(1):1. Nature Publishing Group
Blood Cancer Journal, Vol 11, Iss 1, Pp 1-10 (2021)

Lenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma (MM) but has not been compared to other agents in clinical trials. We retrospectively compared bortezomib (BT

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dea567af161bdc07548c1280a7d542c
https://pure.eur.nl/en/publications/f4d5ebef-55fa-4986-a0fd-31a0368019df

Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial.

Autor: Klein EM; Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany.; Department of Internal Medicine 5, Klinikum Nuremberg, Paracelsus Medical University, 90419 Nuremberg, Germany., Tichy D; Division of Biostatistics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany., Salwender HJ; Asklepios Tumorzentrum Hamburg, AK Altona and AK St. Georg, 22763 Hamburg, Germany., Mai EK; Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany., Duerig J; Department of Hematology, University Clinic Essen, 45147 Essen, Germany., Weisel KC; Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany., Benner A; Division of Biostatistics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany., Bertsch U; Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany.; National Center for Tumor Diseases, 69120 Heidelberg, Germany., Akhavanpoor M; Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany., Besemer B; Department of Hematology, Oncology and Immunology, University Hospital Tübingen, 72076 Tübingen, Germany., Munder M; Department of Internal Medicine III, University Medical Center Mainz, 55131 Mainz, Germany., Lindemann HW; Department of Hematology and Oncology, Katholisches Krankenhaus Hagen, 58097 Hagen, Germany., Hose D; Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany., Seckinger A; Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany., Luntz S; Coordination Centre for Clinical Trials (KKS) Heidelberg, 69120 Heidelberg, Germany., Jauch A; Institute of Human Genetics, University of Heidelberg, 69120 Heidelberg, Germany., Elmaagacli A; Department of Hematology and Oncology, Asklepios Hospital Hamburg St. Georg, 20099 Hamburg, Germany., Fuhrmann S; Department of Hematology and Oncology, Helios Hospital Berlin Buch, 13125 Berlin, Germany., Brossart P; Department of Internal Medicine, Oncology, Hematology, Immuno-Oncology and Rheumatology/Clinical Immunology, University Hospital Bonn, 53127 Bonn, Germany., Goerner M; Department of Hematology, Oncology and Palliative Care, Klinikum Bielefeld, 33604 Bielefeld, Germany., Bernhard H; Internal Medicine V, Klinikum Darmstadt, 64283 Darmstadt, Germany., Raab MS; Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany., Blau IW; Medical Clinic, Charité University Medicine Berlin, 13353 Berlin, Germany., Haenel M; Department of Internal Medicine III, Klinikum Chemnitz, 09116 Chemnitz, Germany., Scheid C; Department of Internal Medicine I, University Hospital Cologne, 50937 Cologne, Germany., Goldschmidt H; Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany.; National Center for Tumor Diseases, 69120 Heidelberg, Germany., On Behalf Of The German-Speaking Myeloma Multicenter Group Gmmg

Publikováno v: Cancers [Cancers (Basel)] 2021 Sep 28; Vol. 13 (19). Date of Electronic Publication: 2021 Sep 28.

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.

Autor: Mai EK; Department of Internal Medicine V, University Hospital Heidelberg and National Center for Tumor Diseases (NCT) Heidelberg on behalf of the German-Speaking Myeloma Multicenter Group (GMMG), Heidelberg, Germany., Bertsch U; Department of Internal Medicine V, University Hospital Heidelberg and National Center for Tumor Diseases (NCT) Heidelberg on behalf of the German-Speaking Myeloma Multicenter Group (GMMG), Heidelberg, Germany., Dürig J; Department of Hematology, University Hospital Essen, Essen, Germany., Kunz C; Division of Biostatistics, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany., Haenel M; Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany., Blau IW; Medical Clinic, Charité University Medicine Berlin, Berlin, Germany., Munder M; Department of Internal Medicine III, University Medical Center Mainz, Mainz, Germany., Jauch A; Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany., Schurich B; Coordination Centers for Clinical Trials (KKS), University Hospital Heidelberg, Heidelberg, Germany., Hielscher T; Division of Biostatistics, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany., Merz M; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany., Huegle-Doerr B; Department of Internal Medicine V, University Hospital Heidelberg and National Center for Tumor Diseases (NCT) Heidelberg on behalf of the German-Speaking Myeloma Multicenter Group (GMMG), Heidelberg, Germany., Seckinger A; Department of Internal Medicine V, University Hospital Heidelberg and National Center for Tumor Diseases (NCT) Heidelberg on behalf of the German-Speaking Myeloma Multicenter Group (GMMG), Heidelberg, Germany., Hose D; Department of Internal Medicine V, University Hospital Heidelberg and National Center for Tumor Diseases (NCT) Heidelberg on behalf of the German-Speaking Myeloma Multicenter Group (GMMG), Heidelberg, Germany., Hillengass J; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany., Raab MS; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany., Neben K; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany., Lindemann HW; Department of Hematology and Oncology, Katholisches Krankenhaus Hagen, Hagen, Germany., Zeis M; Department of Hematology, Asklepios Hospital St. Georg Hamburg, Hamburg, Germany., Gerecke C; Department of Hematology and Oncology, Helios Hospital Berlin Buch, Berlin, Germany., Schmidt-Wolf IG; Center for Integrated Oncology, University Hospital Bonn, Bonn, Germany., Weisel K; Department of Hematology, Oncology and Immunology, University Hospital Tübingen, Tübingen, Germany., Scheid C; Department of Internal Medicine I, University Hospital Köln, Köln, Germany., Salwender H; Department of Hematology and Oncology, Asklepios Hospital Hamburg Altona, Hamburg, Germany., Goldschmidt H; Department of Internal Medicine V, University Hospital Heidelberg and National Center for Tumor Diseases (NCT) Heidelberg on behalf of the German-Speaking Myeloma Multicenter Group (GMMG), Heidelberg, Germany.

Publikováno v: Leukemia [Leukemia] 2015 Aug; Vol. 29 (8), pp. 1721-9. Date of Electronic Publication: 2015 Mar 19.